Volume 29, Issue 133 (March & April 2021)                   J Adv Med Biomed Res 2021, 29(133): 118-122 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Jafari F, Kordafshari G, Norouzi Gheidari N, Ayati M H. Successful Treatment of Refractory Autoimmune Hemolytic Anemia (AIHA) in a Child, Based on Iranian Traditional Medicine: A Case Report. J Adv Med Biomed Res 2021; 29 (133) :118-122
URL: http://journal.zums.ac.ir/article-1-5964-en.html
1- Dept. of Traditional Medicine, School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran
2- School of Physical and Occupational Therapy, Faculty of Medicine, McGill University, Montreal, QC, Canada
3- Dept. of Medical History, School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran , ayatimd@gmail.com
Abstract:   (141842 Views)

Autoimmune hemolytic anemia (AIHA) is a heterogeneous and relatively unknown disease caused by premature immune destruction of red blood cells. While its occurrence is uncommon among children, it is sometimes severe and resistant to treatment. The warm-reactive type contains 70% to 80% of all cases, in which the first-line treatment is considered to be a steroid. Moreover, splenectomy, rituximab (a monoclonal antibody), and immunosuppressive drugs are used in refractory cases, with unclear efficacy and deep suppression of the immune system, which consequently lead to various side effects. This study reports the successful treatment of a life-threatening case using a new method. In this regard, it was stated that using the capacity of Iranian traditional medicine (ITM) as one of the complementary therapies can help in the treatment of this disease.
In this case report, we documented the successful treatment of a severe and refractory warm AIHA in a boy, who was resistant to the currently recommended treatments such as corticosteroids, rituximab, and cyclosporine at different time periods. Based on ITM, a novel treatment was performed, which was daily swallowing 4-6 live small freshwater fishes (from Cyprinidae family) for an eight-week period and later being tapered. As a result, this treatment had a rapid response time with no side effects. At the time of performing this study, the patient was in his 5th-year disease-free period. For future research, we recommend the researchers to study the use of this novel treatment in case of resistance to the current established therapies of warm AIHA disease.

Full-Text [PDF 462 kb]   (153242 Downloads) |   |   Full-Text (HTML)  (2967 Views)  

✅ As a result, this treatment had a rapid response time with no side effects. At the time of performing this study, the patient was in his 5th-year disease-free period. For future research, we recommend the researchers to study the use of this novel treatment in case of resistance to the current established therapies of warm AIHA disease.


Type of Study: Case Report Article | Subject: Clinical Medicine
Received: 2020/04/3 | Accepted: 2020/07/16 | Published: 2020/12/4

References
1. Park SH. Diagnosis and treatment of autoimmune hemolytic anemia: classic approach and recent advances. Blood Res. 2016;51(2):69-71. [DOI:10.5045/br.2016.51.2.69]
2. Liebman HA, Weitz IC. Autoimmune hemolytic anemia. Med Clin North Am. 2017;101(2):351-9 [DOI:10.1016/j.mcna.2016.09.007]
3. Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology. 2018;2018(1):382-9. [DOI:10.1182/asheducation-2018.1.382]
4. Chaudhary RK, Das SS. Autoimmune hemolytic anemia: From lab to bedside. Asian J Transfus Sci. 2014;8(1):5-12 [DOI:10.4103/0973-6247.126681]
5. Naik R. Warm autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 2015;29:445-53. [DOI:10.1016/j.hoc.2015.01.001]
6. Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev. 2015;14:304-13. [DOI:10.1016/j.autrev.2014.11.014]
7. Dierickx D, Kentos A, Delannoy A. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. J Am Soc Hematol. 2015;125(21):3223-9. [DOI:10.1182/blood-2015-01-588392]
8. Jäger U, Barcellini W, Broome CM. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648. [DOI:10.1016/j.blre.2019.100648]
9. Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017;129:2971-9. [DOI:10.1182/blood-2016-11-693689]
10. Makis A, Kanta Z, Kalogeropoulos D, Chaliasos N. Anti-CD20 treatment of autoimmune hemolytic anemia refractory to corticosteroids and azathioprine: A pediatric case report and mini review. Case Rep Hematol. 2018;2018:8471073. [DOI:10.1155/2018/8471073]
11. Ducassou S, Leverger G, Fernandes H, et al. Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. Br J Haematol.2017;177:751-8. [DOI:10.1111/bjh.14627]
12. Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol. 2018;14(10):857-72. [DOI:10.1080/1744666X.2018.1521722]
13. Azam Khan M. Exir Azam (Persian) Volume 1. Tehran: Institute of Meical History, Islamic Medicine and Complementary Medicine; 2008.
14. Ibn-e-Sina AH. Al-qanun fit-tib [The canon of medicine]. Beirut, Lebanon: Alaalami Beirut lib Press; 2005.
15. Ibn al-Nafis. Ash-shamel fit-teb. Beirut: Dar Al-kotob Al-ilmiyah Publication; 2004.

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb